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Background: Aspirin resistance in patients with diabetes is recognized. However, the prevalence and
related risk factors for aspirin resistance in elderly patients with Type 2 diabetes have not been reported,
which is why we undertook this study.
Methods: One hundred and forty elderly patients (age, 73.84 8.02 years) with Type 2 diabetes receiving
daily aspirin therapy (75 mg) over 1 month were recruited. Platelet aggregation was measured by light
transmission aggregometry (LTA) and thrombelastography (TEG) platelet mapping assay. The deﬁnitions
of aspirin resistance were 20% or greater arachidonic acid-induced and 70% or greater adenosine
diphosphate-induced aggregation by LTA. Aspirin semiresponders were deﬁned as meeting one (but not
both) of these criteria. Aspirin resistance by TEG was deﬁned as 50% or greater aggregation induced by
arachidonic acid.
Results: By LTA, 6 (4.3%) patients with Type 2 diabetes were found to be resistant to aspirin therapy; 44
(31.4%) patients were semiresponders. By TEG, 31 patients (22.1%) were aspirin resistant. Of the 31
patients who were aspirin-resistant by TEG, 3 were aspirin-resistant by LTA. Eight of 44 semiresponders
by LTA were aspirin-resistant by TEG. In the multivariate logistic regression analysis, being female (odds
ratio: 5.54, 95% conﬁdence interval: 1.17e27.47, p¼ 0.036) and homocysteine levels (odds ratio: 1.15, 95%
conﬁdence interval: 1.00e1.31, p¼ 0.043) were signiﬁcant risk factors for aspirin resistance by TEG.
Conclusion: The prevalence of aspirin resistance in elderly patients with Type 2 diabetes was considerably
higher in female patients and in patients with higher serum levels of homocysteine.
Copyright  2011, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Elderly people with diabetes have twice the prevalence of
mortality of age-matched controls without diabetes1. The principal
killer is macrovascular diseases. Aspirin is currently recommended
by the American Diabetes Association for diabetic patients aged
older than 40 years without cardiovascular disease2. However,
some studies have suggested a lower effect of primary prevention
of cardiovascular disease with low-dose aspirin in diabetic patients
compared with other risk factors for cardiovascular disease3. Lack
of adequate inhibition of platelets from aspirin therapy is known
as “aspirin resistance.” The prevalence of aspirin resistance is
10%e40% for patients with diabetes4.ao, First Geriatric Cardiology
Rd, Beijing 100853, China.
erest.
iwan Society of Geriatric EmergenResults of studies investigating whether aspirin resistance is
increased in diabetic patients compared with nondiabetic patients
are inconsistent5e7, but the consequences of insufﬁcient inhibition
of platelets during aspirin treatment could be substantial. Some
studies suggested an association of aspirin resistance with
smoking, hypertension, hypercholesterolemia, HbA1c levels, body
mass index, levels of C-reactive protein, age, and being female5,7e11.
Interestingly, scholars revealed that hyperhomocysteinemia is an
independent risk factor for macroangiopathy and mortality in
diabetic patients, and that homocysteine (Hcy) is also associated
with diabetic silent stroke and cognitive impairment12. Given the
relationship between Hcy and diabetes, we hypothesized that Hcy
may be associated with aspirin resistance in diabetic patients.
Furthermore, the prevalence and related risk factors for aspirin
resistance in elderly patients with diabetes mellitus have not been
reported. We therefore evaluated the prevalence of aspirin resis-
tance to test the hypothesis that aspirin resistance may be associ-
ated with Hcy and other potential risk factors in elderly patients
with Type 2 diabetes.cy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
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2.1. Ethical approval of the study protocol
This study complied with the Declaration of Helsinki. It was
approved by the Scientiﬁc and Ethics Review Board of the First
Geriatric Cardiology Division, Chinese PLA General Hospital, Bei-
jing. All participants provided written informed consent to be
included in the study.
2.2. Participants
We enrolled 140 patients from April 2008 to June 2010. Patients
were recruited from the Wangshoulu area of Beijing. Patients were
aged 60 years or older and were being treated for Type 2 diabetes;
all patients were on regular treatment with aspirin (75e100 mg
daily over 1 month). The exclusion criteria were hypersensitivity to
aspirin; the use of clopidogrel, ticlopidine, dipyridamole, or other
nonsteroidal anti-inﬂammatory drugs, heparin, or lowemolecular
weight heparin; a major surgical procedure within 1 week before
study enrollment; family or personal history of bleeding disorders;
platelet count lower than 150,000/mL or higher than 450,000/mL;
hemoglobin level lower than 8 g/dL; history of myeloproliferative
disorders; or a history of drug-induced thrombocytopenia.
2.3. Blood sampling
Blood samples were obtained from patients between 7 AM and 9
AM, 2e12 hours after ingestion of the last dose of aspirin to elimi-
nate the effects of circadian variation on platelet function. The ﬁrst
2 mL of blood drawn by venipuncture through a 21-gauge needle
were discarded. Tubes containing 3.2% sodium citrate were used for
light transmission aggregometry (LTA) and thrombelastography
(TEG). One tube that contained lithium heparin was also used for
TEG. In addition, one tube that contained a clavicular tilt angle
difference (a mixture of citrate, theophylline, adenosine, and
dipyridamole) was collected for measurement of CD62P (P-selec-
tin) and PAC-1 (activated GP IIb/IIIa receptors). Moreover, four
conventional tubes were used for the percentage activity of HbA1c,
high-sensitivity C-reactive protein, Type B natriuretic peptide, Hcy,
and protein C; the percentage activity of antithrombin III; routine
measurement of blood components and blood lipids; and other
biochemistry measurements. All assays were processed within 2
hours of blood sampling.
2.4. Light transmission aggregometry
Platelet aggregationwas assessed in platelet-rich plasma at 37C
by LTA. Samples were centrifuged at 800 revolutions per minute for
5 minutes to obtain native platelet-rich plasma. The platelet count
was assessed using a standard cell counter. Platelet-poor plasma
was obtained by centrifugation of the remaining blood at 4,000
revolutions per minute at room temperature for 8 minutes.
Aggregation was measured with a ChronoLog Aggregometer
(Chronolog, Havertown, PA, USA). Aggregation was expressed as
the maximal percentage change in light transmittance from base-
line after the addition of arachidonic acid (AA; 0.5mM) and aden-
osine diphosphate (ADP; 10mM) using platelet-poor plasma as the
reference.
2.5. TEG platelet-mapping assay
The TEG platelet-mappingassay from Haemoscope Corporation
(Niles, IL, USA) relies on the measurement of clot strength to
enable quantitative analyses of platelet function. AA (1mM/L) wasadded to activator F to measure the degree of thromboxane
A2-induced platelet aggregation. This methodology is described
elsewhere13.
2.6. Markers of platelet reactivity
Platelet activation was determined by assessing platelet surface
expression of PAC-1 and CD62P after natural activation using ﬂow
cytometry (BD Biosciences, San Jose, CA, USA) as previously
described14. The antibodies of R-phycoerythrin-conjugated anti-
CD62P (recognizes P-selectin), ﬂuorescein isothiocyanate-
conjugated PAC-1 (recognizes the active GPIIb/IIIa receptor), and
R-phycoerythrin-conjugated CD61 (recognizes the total population
of GPIIb/IIIa receptors) were obtained from BD Biosciences. Results
of CD62P and PAC-1 were expressed as percentages.
2.7. Deﬁnition of aspirin resistance
The deﬁnitions of aspirin resistance were 20% or higher AA-
induced and 70% or higher ADP-induced aggregation according to
LTA. Aspirin semiresponders were deﬁned as meeting one (but not
both) of the criteria described above7,15. By TEG, aspirin resistance
was deﬁned as 50% or higher aggregation induced by AA13.
2.8. Statistical analyses
Continuous variables are mean standard deviation. For
continuous variables, analyses of univariate tests or Kruskal-Wallis
tests (if the distributionwas not normal) were used to compare the
three groups deﬁned by aggregation. The Student t test or Mann-
Whitney U two-sample tests (if the distribution was not normal)
were used to compare the continuous variables between the two
groups. Categorical data and proportions were analyzed using the
c2 test. A p value less than 0.05 was considered signiﬁcant.
Parameters signiﬁcantly related with the presence of aspirin
resistance were determined using binary logistic regression anal-
yses (SPSS Windows, version 14.0; SPSS, Inc., Chicago, IL, USA).
3. Results
3.1. Patient characteristics
Demographics, as well as comparison of aspirin-resistant
patients, aspirin semiresponders, and aspirin-sensitive patients
by LTA and TEG are provided in Tables 1 and 2. Aspirin resistance,
aspirin semiresponders, and a combined group of aspirin resistance
plus aspirin semiresponders as measured by LTA were not associ-
ated with signiﬁcant differences with regard to age; being female;
being a current smoker; having hypertension, coronary artery
disease, cerebrovascular disease, or peripheral arterial occlusive
disease; and baseline platelet count. Serum Hcy levels were high in
patients with aspirin resistance. Aspirin semiresponders were less
likely to take angiotensin-converting enzyme inhibitors (ACEIs) or
angiotensin receptor blockers (ARBs) than aspirin-sensitive
patients (p¼ 0.020). Moreover, there were fewer patients in the
combined group of aspirin-resistant patients and aspirin semi-
responders receiving ACEIs or ARBs therapy than aspirin-sensitive
patients (p¼ 0.011).
By TEG, there were no signiﬁcant differences between the
aspirin-resistant and aspirin-sensitive group when comparing age;
being a current smoker; having hypertension, coronary artery
disease, cerebrovascular disease, or peripheral arterial occlusive
disease; and baseline platelet count. There were signiﬁcantly more
women in the aspirin-resistant group (p¼ 0.004). Aspirin-resistant
patients had higher levels of Hcy in serum, triglyceride levels, and
Table 1
Patient demographics by LTA
Patient demographics Aspirin-resistant
(n¼ 6)
Aspirin semiresponders
(n¼ 44)
Aspirin-resistant
or semiresponders (n¼ 50)
Aspirin-sensitive
(n¼ 90)
pa pb
Demographics
Age (yr) 70.20 4.20 73.76 7.97 73.30 7.65 74.21 8.31 0.576 0.591
Female, n (%) 2 (33.3) 9 (20.4) 11 (22) 21 (23.3) 0.850 0.857
Current smoker, n (%) 1 (16.7) 4(9.1) 5 (10) 3 (3.3) 0.200 0.103
Hypertension, n (%) 4 (66.7) 34 (77.2) 38 (76) 62 (68.8) 0.580 0.156
History of coronary artery disease, n (%) 4 (66.7) 23 (52.2) 27 (54) 54 (60) 0.630 0.490
Cerebrovascular disease, n (%) 1 (16.7) 21 (47.7) 22 (44) 30 (33.3) 0.153 0.210
PAOD, n (%) 0 (0) 4 (9.1) 4 (8) 16 (17.7) 0.238 0.113
Biochemistry
Homocysteine (mmol/L) 20.68 3.84 17.02 4.49 17.54 4.56 15.58 5.34 0.123 0.630
HbA1c (%units) 7.75 1.98 6.98 1.35 6.39 1.40 7.37 2.07 0.456 0.415
BMI (kg/m2) 24.89 2.2.36 24.87 1.93 25.47 3.01 24.58 2.75 0.603 0.316
hs-CRP (mg/dL) 0.33 0.27 1.38 3.66 0.84 2.73 2.04 8.64 0.841 0.599
BNP (pg/mL) 125.92 138.74 45.81 33.68 97.78 230.09 137.10 274.10 0.465 0.324
PAC-1 (%) 35.36 29.75 50.28 29.08 47.95 27.22 38.67 27.89 0.223 0.167
CD62P (%) 13.48 14.57 12.17 17.85 12.34 17.20 18.8 25.81 0.462 0.215
Protein C activity (%) 87.60 30.60 97.87 29.45 118.66 47.60 103.39 29.94 0.192 0.695
Antithrombin III activity (%) 86.5 7.23 94.89 9.15 99.90 12.85 92.37 12.46 0.748 0.456
Fasting serum glucose (mmol/L) 8.47 6.61 6.72 1.27 6.87 1.39 6.04 1.20 0.956 0.779
Total cholesterol (mmol/L) 4.37 0.31 4.47 0.62 4.56 0.88 5.05 2.18 0.411 0.181
Triglyceride (mmol/L) 1.77 1.20 1.39 0.46 1.69 0.72 1.60 0.91 0.462 0.580
Uric acid (mmol/L) 384.15 27.08 311.26 48.16 297.00 130.31 342.50 110.61 0.841 0.841
HDL cholesterol (mmol/L) 1.07 0.19 1.25 0.27 1.17 0.28 1.30 0.35 0.068 0.071
LDL cholesterol (mmol/L) 2.77 0.47 2.63 0.44 2.73 0.70 2.85 0.84 0.519 0.250
Creatinine (mmol/lL) 83.7 12.9 95.3 12.9 93.85 20.35 79.5 14.8 0.541 0.295
Platelet count (/mL) 217 35.35 215.38 34.79 215.70 32.87 209.55 78.50 0.972 0.813
Medications taken
ACEIs/ARBs, n (%) 1 (16.7) 10 (22.7)c 11 (22) 39 (43.3)c 0.039 0.011
CCBs, n (%) 2 (33.3) 18 (40.9) 20 (40) 46 (51.1) 0.424 0.200
Statins, n (%) 2 (33.3) 17 (38.6) 19 (38) 35 (38.8) 0.964 0.915
Daily aspirin dose (mg), n (%)
75 2 (33.3) 15 (34.1) 17 (34) 43 (47.7) 0.287 0.114
100 4 (66.7) 29 (65.9) 33 (66) 47 (52.3) 0.287 0.114
ACEIs¼ angiotensin-converting enzyme inhibitor; ARBs¼ angiotensin receptor blocker; CCBs¼ calcium-channel blockers; BMI¼ body mass index; BNP¼ type-B natriuretic
peptide; HDL¼ high-density lipoprotein; hs-CRP¼ high-sensitivity C-reactive protein; LDL¼ low-density lipoprotein; LTA¼ light transmission aggregometry; PAC-
1¼ procaspase activating compound 1; PAOD¼ peripheral arterial occlusive disease.
a The p value comparing aspirin-resistant patients, aspirin semiresponders, and aspirin-sensitive patients.
b The p value comparing combined group of aspirin-resistant patients and aspirin semiresponders with aspirin-sensitive patients.
c Signiﬁcant differences between groups, p< 0.05.
L. Liu et al114fasting serum glucose levels compared with aspirin-sensitive
patients (p¼ 0.030, p¼ 0.003, and p¼ 0.049, respectively).
Aspirin-sensitive patients were more likely to take statins than
aspirin-resistant patients (p¼ 0.012). PAC-1 levels were high in the
aspirin-resistant group, but this difference did not reach statistical
signiﬁcance (p¼ 0.224).
3.2. Testing of platelet aggregation
By LTA, six patients (4.3%) were aspirin resistant. An additional
44 patients (31.4%) were aspirin semiresponders. By TEG, 31
patients (22.1%) were aspirin resistant. Of the 31 patients whowere
aspirin resistant by TEG, 3 were aspirin resistant by LTA. In addition,
eight of 44 semiresponders by LTA were aspirin resistant by TEG.
The kappa statistic between these two methods was 0.125 [95%
conﬁdence interval (CI): 0.0636e0.2002].
3.3. Multiple logistic regression analysis
We did not ﬁnd signiﬁcant risk factors by LTA. However, by
TEG, we undertook a binary logistic regression analysis. This
revealed that being female [odds ratio (OR): 5.54, 95% CI:
1.17e27.47, p¼ 0.036] and Hcy levels (OR: 1.15, 95% CI: 1.00e1.31,
p¼ 0.043) were signiﬁcant risk factors for aspirin resistance by
TEG (Table 3).4. Discussion
In the present study, we demonstrated, for the ﬁrst time, that
the prevalence of aspirin resistance by LTA was 4.3% in elderly
people with diabetes, and that the proportion of semiresponders to
aspirin treatment was 31.4%. These ﬁndings implied that only 64.3%
of patients with diabetes may beneﬁt from aspirin therapy.
DiChiara et al6 suggested that a low prevalence (0e2%) of aspirin
resistance was observed with all aspirin doses (81 mg/d, 162 mg/d,
and 325 mg/d for 4 weeks) in 120 patients with stable coronary
artery disease as determined by AA-induced LTA. Lordkipanidze
et al16 demonstrated that the prevalence of aspirin resistance in 201
patients with stable coronary artery disease varied according to the
assay used: 2.8% for LTAAA and LTAADP. Despite these differences, in
a relatively large study by Gum et al7, 5.5% of patients were aspirin-
resistant by LTAAA and LTAADP in 325 patients with stable coronary
artery disease. This ﬁgure is similar to that in the present study.
We also demonstrated that TEG might be a more sensitive test
for aspirin resistance than LTA. In a study of 120 patients with
coronary artery disease taking aspirin, 9% were aspirin-resistant by
TEG8. In the present study, 31 patients (22.1%) were aspirin resis-
tant according toTEG. Similar results with respect to the prevalence
of aspirin resistance in diabetic patients using the platelet function
analyzer (PFA-100) were reported by Cohen et al10 (23%) and Fateh-
Moghadam et al9 (21.5%). A particular advantage of the TEG Platelet
Table 2
Patient demographics by TEG
Patient demographics All patients (n¼ 140) Aspirin-resistant (n¼ 31) Aspirin-sensitive (n¼ 109) p
Demographics
Age (yr) 73.84 8.02 72.56 9.19 76.75 6.07 0.157
Female, n (%) 32 (22.8) 13 (41.9) 19 (17.4) 0.004
Current smoker, n (%) 8 (5.7) 1 (3.2) 7 (6.4) 0.748
Hypertension, n (%) 100 (71.4) 22 (70.9) 78 (71.5) 0.948
History of coronary artery disease, n (%) 81 (57.8) 21 (67.7) 60 (55) 0.141
Cerebrovascular disease, n (%) 52 (37.1) 14 (45.1) 38 (34.8) 0.295
PAOD, n (%) 20 (14.2) 4 (12.9) 16 (14.6) 0.858
Biochemistry
Homocysteine (mmol/L) 16.67 5.49 19.35 6.81 16.08 5.62 0.030
HbA1c (%units) 7.42 1.87 7.38 2.36 7.11 1.50 0.756
BMI (kg/m2) 24.73 2.36 26.10 3.33 24.68 2.89 0.051
hs-CRP (mg/dL) 1.63 6.54 1.13 1.89 1.17 5.38 0.970
BNP (pg/mL) 99.24 203.11 353.9 696.16 109.10 224.5 0.564
PAC-1 (%) 42.39 29.31 47.07 30.04 38.42 25.58 0.224
CD62P (%) 16.10 22.71 14.08 20.76 15.81 20.88 0.776
Protein C activity (%) 98.93 28.88 118.86 40.07 113.91 37.84 0.728
Antithrombin III activity (%) 92.89 10.42 105.70 12.28 100.02 14.71 0.147
Fasting serum glucose (mmol/L) 6.36 1.26 7.62 2.09 6.74 1.77 0.049
Total cholesterol (mmol/L) 4.81 1.59 5.61 1.29 5.18 4.91 0.685
Triglyceride (mmol/L) 1.53 0.78 2.05 0.78 1.50 0.75 0.003
Uric acid (mmol/L) 335.56 89.96 331.92 117.11 298.50 98.10 0.239
HDL cholesterol (mmol/L) 1.26 0.31 1.20 0.30 1.32 0.33 0.146
LDL cholesterol (mmol/L) 2.76 0.67 3.49 1.13 2.97 0.78 0.080
Creatinine (mmol/L) 85.2 20.8 83.94 15.64 89.96 17.23 0.696
Platelet count (/mL) 211.25 68.46 192.45 24.55 177.95 36.88 0.130
Medications taken
ACEIs/ARBs, n (%) 50 (35.7) 12 (38.7) 38 (34.8) 0.693
CCBs, n (%) 66 (47.1) 18 (58.1) 48 (44) 0.167
Statins, n (%) 54 (38.5) 6 (19.3) 48 (44) 0.012
Daily aspirin dose (mg), n (%)
75 60 (42.9) 12 (38.7) 48 (44) 0.596
100 80 (57.1) 19 (61.3) 61 (56) 0.596
ACEIs¼ angiotensin-converting enzyme inhibitor; ARBs¼ angiotensin receptor blocker; CCBs¼ calcium-channel blockers; BMI¼ body mass index; BNP¼ type-B natriuretic
peptide; HDL¼ high-density lipoprotein; hs-CRP¼ high-sensitivity C-reactive protein; LDL¼ low-density lipoprotein; PAC-1¼ procaspase activating compound 1;
PAOD¼ peripheral arterial occlusive disease; TEG¼ thrombelastography.
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it speciﬁcally measures the platelet contribution to clot strength17.
Hence, the TEG Platelet Mapping system has been used extensively
in clinical practice not only for evaluation of platelet function but
also in the management of hemostasis.
Using a multivariable logistic regression analysis, we demon-
strated that female sex and Hcy levels were independent risk
factors for aspirin resistance in diabetic patients.
One study revealed that, in patients with Type 2 diabetes, Hcy
levels were signiﬁcantly increased compared with healthy indi-
viduals. Hyperhomocysteinemia is an independent risk factor forTable 3
Results of the multiple logistic regression analysis
Parameters B SE Wald df Signiﬁcant
risk
Exp(B) 95% CI for
Exp(B)
Lower Upper
Age 0.035 0.035 0.984 1 0.321 0.966 0.902 1.034
Sex 1.711 0.817 4.386 1 0.036 5.536 1.116 27.465
BMI 0.099 0.160 0.381 1 0.537 1.104 0.807 1.509
Triglyeride 0.642 0.459 1.954 1 0.162 1.900 0.773 4.671
Fasting serum
glucose
0.023 0.279 0.007 1 0.933 0.977 0.565 1.689
LDL cholesterol 0.112 0.247 0.205 1 0.650 1.118 0.689 1.815
Statin therapy 0.025 0.627 0.002 1 0.968 0.975 0.285 3.335
Hcy 0.137 0.068 4.082 1 0.043 1.147 1.004 1.309
Constant 4.524 3.300 1.879 1 0.170 0.011
CI¼ conﬁdence interval; df¼ degrees of freedom; SE¼ standard error.macroangiopathy, microangiopathy, and mortality18. Gonzalez
et al19 subsequently revealed that Hcy levels higher than 16.7 mmol/
L were associated with an increased risk of mortality in blood
samples [relative risk 2.30 (95% CI: 1.02e5.17)] from elderly
patients (>60 years). The present study demonstrated that Hcy
levels were independent risk factors for aspirin resistance in dia-
betic patients. This may be because of the association with endo-
thelial damage, proliferation of smooth muscle cells, and
enhancement of coagulation20,21. Furthermore, Zanin et al22 sug-
gested that Hcy decreased extracellular nucleotide hydrolysis in rat
platelets and Hcy treatment increased platelet aggregation induced
by ADP. These ﬁndings suggest that we should pay more attention
to serum Hcy levels and aspirin resistance, and whether lowering
serum Hcy levels may improve the antiplatelet effects of aspirin.
Several studies reported a relatively higher prevalence of aspirin
resistance in women compared with men7,23,24. The present study
was in accordance with those studies. Nevertheless, in a large study
by Becker et al25, women demonstrated the same (or greater)
decreases in platelet reactivity after aspirin therapy, retaining
slightlymore platelet reactivity comparedwithmen. There could be
two reasons for these inconsistent results. First, a lack of association
of aspirin resistance with clinical events in these studies (including
the present study) has yielded different results regarding sex in
platelet aggregation-related phenotypes. Second, different demo-
graphics among studied populations may play a part in these
differing results. For example, the study by Becker et al25 comprised
patients who were younger, with a higher body mass index, and in
which there were more colored patients than those in the present
L. Liu et al116study. Further study should focus on the events of aspirin resistance
with evaluation of platelet function in the female population.
Recently, some studies implied that certain agents (e.g., ACEIs,
ARBs, statins, and calcium-channel blockers) may decrease platelet
aggregation26e28. In the present study, the number of patients
receiving ACEIs or ARBs therapy with aspirin sensitivity was more
than that of patients whowere aspirin semiresponders and aspirin-
resistant patients. These ﬁndings suggest us that ACEI or ARB
therapy may improve the antiplatelet effects of aspirin. An inter-
esting ﬁnding of the present study was that more aspirin-sensitive
patients took statins than aspirin-resistant patients. A study by
Santos et al29 revealed that atorvastatin combined with aspirin
early in the onset of the acute event signiﬁcantly reduced persistent
thromboxane A2-dependent aspirin resistance in aspirin-free
patients with hypercholesterolemia. These results indicate that
statin therapy in patients with dyslipidemia may ameliorate the
antiplatelet effects of aspirin.
CD62P and PAC-1 are used as markers of platelet activation.
Investigations have suggested that diabetic patients have increased
platelet reactivity (P-selectin expression and PAC-1 binding)
compared with nondiabetic individuals on combined aspirin and
clopidogrel treatment30. Lev et al14 revealed that comparison of
baseline platelet reactivity showed a trend toward higher baseline
P-selectin levels in aspirin-resistant patients than in aspirin-
sensitive patients. In the present study, PAC-1 levels were high in
the aspirin-resistant group by TEG. These results indicate that
increasing platelet reactivity in diabetic patients may be associated
with aspirin resistance. This may be the result of reduction in the
level of endothelial nitric oxide, dyslipidemia, and low-grade
inﬂammation in diabetic patients4.
The present study had one important limitation. The prevalence
of aspirin resistance in elderly patients with diabetes was valid for
the dose of 75e100 mg/d of aspirin, but we did not investigate the
other suggested doses of 162 mg/d and 325 mg/d.
In conclusion, these ﬁndings suggest that a signiﬁcant number
of elderly patients with Type 2 diabetes who have been prescribed
aspirin therapy may not obtain the intended platelet inhibition. We
found that the prevalence of aspirin resistance was considerably
higher in elderly female patients and in elderly patients with higher
serum levels of Hcy. These ﬁndings suggest that the antiplatelet
effect of low-dose aspirin may be decreased or lost in these
patients. We should pay more attention to antiplatelet therapy in
these patients. Further studies are needed to ascertain the mech-
anism of aspirin resistance and strategies for antiplatelet therapy in
elderly diabetic patients with aspirin resistance.
Acknowledgment
This work was supported by the Military Healthcare Fund
07BJZ01 (to L. Fan and J. Cao) and Fund of the Ministry of Science
and Technology of China (2009BAI86B04). All authors had full
access to the data and take responsibility for their integrity. All
authors agree with the manuscript as written.
References
1. Sinclair AJ, Robert IE, Croxson SC. Mortality in older people with diabetes
mellitus. Diabet Med 1997;14:639e647.
2. Ambrosi P, Villani P, Bouvenot G. Antiplatelet therapy for primary prevention
in diabetes. Diabetes Metab 2006;32. 2S52e2S56.3. Sacco M, Pellegrini F, Roncaglioni MC, et al. Primary prevention of cardiovas-
cular events with low-dose aspirin and vitamin E in type 2 diabetic patients:
results of the Primary Prevention Project (PPP) trial. Diabetes Care
2003;26:3264e3272.
4. Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Dia-
betologia 2008;5:385e390.
5. Ertugrul DT, Tutal E, Yildiz M, et al. Aspirin resistance is associated with gly-
cemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus. J Clin
Endocrinol Metab 2010;95:2897e2901.
6. DiChiara J, Bliden KP, Tantry US, et al. The effect of aspirin dosing on platelet
function in diabetic and nondiabetic patients: an analysis from the aspirin-
induced platelet effect (ASPECT) study. Diabetes 2007;56:3014e3019.
7. Gum PA, Kottke-Marchant K, Poggio ED, et al. Proﬁle and prevalence of aspirin
resistance in patients with cardiovascular disease. Am J Cardiol
2001;88:230e235.
8. Gurbel PA, Bliden K, DiChiara J, et al. Evaluation of dose-related effects of
aspirin on platelet function: results from the Aspirin-Induced Platelet Effect
(ASPECT) study. Circulation 2007;115:3156e3164.
9. Fateh-Moghadam S, Plockinger U, Cabeza N, et al. Prevalence of aspirin resis-
tance in patients with type 2 diabetes. Acta Diabetol 2005;42:99e103.
10. Cohen HW, Crandall JP, Hailpern SM, et al. Aspirin resistance associated with
HbA1c and obesity in diabetic patients. J Diabetes Complications
2008;22:224e228.
11. Kahraman G, Sahin T, Kilic T, et al. The frequency of aspirin resistance and its
risk factors in patients with metabolic syndrome. Int J Cardiol 2007;115:
391e396.
12. Araki A. Homocysteine and diabetic macroangiopathy. Nippon Rinsho
2006;64:2153e2158 [in Japanese].
13. Tantry U, Bliden K, Gurbel PA. Overestimation of platelet aspirin resistance
detection by thromboelastograph platelet mapping and validation by
conventional aggreagometry using arachidonic acid stimulation. J Am Coll
Cardiol 2005;46:1705e1709.
14. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in
patients undergoing percutaneous coronary intervention: the role of dual drug
resistance. J Am Coll Cardiol 2006;47:27e33.
15. Dussaillant NG, Zapata MM, Fardella BP, et al. Frequency and characteristics of
aspirin resistance in Chilean cardiovascular patients. Rev Med Chil
2005;133:409e417 [in Spanish].
16. Lordkipanidze M, Pharand C, Schampaert E, et al. A comparison of six major
platelet function tests to determine the prevalence of aspirin resistance in
patients with stable coronary artery disease. Eur Heart J 2007;28:1702e1708.
17. Michelson AD. Methods for the measurement of platelet function. Am J Cardiol
2009;103:20Ae26A.
18. Zbidi H, Redondo PC, Lopez JJ, et al. Homocysteine induces caspase activation
by endoplasmic reticulum stress in platelets from type 2 diabetics and healthy
donors. Thromb Haemost 2010;103:1022e1032.
19. Gonzalez S, Huerta JM, Fernandez S, et al. Homocysteine increases the risk of
mortality in elderly individuals. Br J Nutr 2007;97:1138e1143.
20. De Jong SC, Van den Berg M, Rauwerda JA, et al. Hyperhomocysteinemia and
atherothrombotic disease. Semin Thromb Hemost 1998;24:381e385.
21. Jacobsen DW. Homocysteine and vitamins in cardiovascular disease. Clin Chem
1998;44:1833e1843.
22. Zanin RF, Campesato LF, Braganhol E, et al. Homocysteine decreases extracel-
lular nucleotide hydrolysis in rat platelets. Thromb Res 2009;125:e87ee92.
23. Ivandic BTGE, Schlick P, Staritz P, et al. Determination of aspirin responsive-
ness by use of whole blood platelet aggregometry. Clin Chem
2007;53:614e619.
24. Shen H, Herzog W, Drolet M, et al. Aspirin Resistance in healthy drug-naive
men versus women (from the Heredity and Phenotype Intervention Heart
Study). Am J Cardiol 2009;104:606e612.
25. Becker DM, Segal J, Vaidya D, et al. Sex differences in platelet reactivity and
response to low-dose aspirin therapy. JAMA 2006;295:1420e1427.
26. Skowasch D, Viktor A, Schneider-Schmitt M, et al. Differential antiplatelet
effects of angiotensin converting enzyme inhibitors: comparison of ex vivo
platelet aggregation in cardiovascular patients with ramipril, captopril and
enalapril. Clin Res Cardiol 2006;95:212e216.
27. Schafer A, Fraccarollo D, Eigenthaler M, et al. Rosuvastatin reduces platelet
activation in heart failure: role of NO bioavailability. Arterioscler Thromb Vasc
Biol 2005;25:1071e1077.
28. Ajjan R, Grant PJ. Coagulation and atherothrombotic disease. Atherosclerosis
2006;186:240e259.
29. Santos MT, Fuset MP, Ruano M, et al. Effect of atorvastatin on platelet
thromboxane A(2) synthesis in aspirin-treated patients with acute myocardial
infarction. Am J Cardiol 2009;104:1618e1623.
30. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function proﬁles in
patients with type 2 diabetes and coronary artery disease on combined aspirin
and clopidogrel treatment. Diabetes 2005;54:2430e2435.
